• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neoplasia: an international journal for oncology research >Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
【24h】

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2

机译：埃弗洛米斯加上高级乳腺癌的exemestane：从Bolero-2的Subanalyses评论

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers. Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways. Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway aberrations are common in breast cancer, with increased PI3K/AKT/mTOR signaling associated with resistance to endocrine and human epidermal growth factor receptor 2 (HER2)–targeted therapies. The mTOR inhibitor everolimus, in combination with exemestane, has been approved for patients with advanced hormone receptor–positive/HER2-negative breast cancer who progress on prior nonsteroidal aromatase inhibitor therapy based on results reported in the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study. This review will summarize the overall findings from BOLERO-2 and will consider available subanalyses by age, Asian origin, visceral or bone metastases, and prior therapy, with the aim of identifying populations most likely to benefit from everolimus therapy. The review will also summarize safety findings and their management and the effects of everolimus on quality of life.
机译：激素受体阳性乳腺癌通常用内分泌疗法进行管理。然而，对内分泌治疗的抗性导致疾病进展，大部分乳腺癌。通过了解内分泌抵抗的机制，涉及牵引途径和靶标的鉴定导致靶向这些途径的新药。磷酸磷酸酯3-激酶/蛋白激酶B /哺乳动物靶标在乳腺癌中是常见的乳腺癌常见的，其与抗内分泌和人表皮生长因子受体2相关的增加的PI3K / AKT / MTOR信号传导（HER2 ） - 可治疗的疗法。 MTOR抑制剂everolimus与Exemestane相结合，已被批准用于高级激素受体阳性/ HER2阴性乳腺癌患者，他基于口腔胃癌患者-2的乳腺癌试验中报告的结果进行了先前的非甾族芳香酶抑制作用疗法（ Bolero-2）研究。该审查将总结Bolero-2的整体调查结果，并将通过年龄，亚洲来源，内脏或骨转移和先前治疗考虑可用的子α，其目的是识别最有可能从everolimus疗法中受益的人群。审查还将总结安全调查结果及其管理以及艾莫莫斯对生活质量的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号